Adaptive Biotechnologies (ADPT) said Tuesday that Medicare administrative contractor Palmetto GBA has expanded coverage of the biotechnology company's clonoSEQ test service to monitor mantle cell lymphoma treatment-free remission.
The expanded service allows patients who have completed treatment for mantle cell lymphoma to have coverage for receiving clonoSEQ testing every six months for up to five years during treatment-free remission, and annual testing thereafter until disease recurrance is detected, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.